Seoul, South Korea

Eun-Joo Roh

USPTO Granted Patents = 2 

Average Co-Inventor Count = 18.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2015-2016

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Eun-Joo Roh: Innovator in Pharmaceutical Chemistry

Introduction

Eun-Joo Roh is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of 2 patents, her work focuses on addressing critical health issues through innovative solutions.

Latest Patents

Eun-Joo Roh's latest patents include a phenoxypropanol derivative and a pharmaceutical composition that incorporates this derivative. This invention relates to a novel phenoxypropanol derivative, represented by the structure of Chemical Formula I, and its racemate, pharmaceutically acceptable salts, solvates, and hydrates. The derivative is designed for blocking T-type calcium channels and/or TREK channels, which can be crucial in preventing and treating associated diseases. Additionally, she has developed benzoarylureido compounds aimed at the prevention and treatment of neurodegenerative brain diseases, including Alzheimer's disease, dementia, and Parkinson's disease.

Career Highlights

Eun-Joo Roh is affiliated with the Korea Institute of Science and Technology, where she conducts her research and development activities. Her work has garnered attention for its potential impact on treating complex neurological conditions.

Collaborations

Eun-Joo collaborates with notable colleagues, including Kye-Jung Shin and Hoh-Gyu Hahn, who contribute to her research endeavors.

Conclusion

Eun-Joo Roh's innovative work in pharmaceutical chemistry exemplifies the importance of research in developing new treatments for serious health conditions. Her contributions continue to advance the field and offer hope for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…